EP3265122
COMBINATION OF PEMBROLIZUMAB AND ERIBULIN FOR TREATING TRIPLE-NEGATIVE BREAST CANCER
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
3.3.2016EP published:
4.5.2022EP application number:
16710891.9
EPO information:
European Patent Register
Max expiry date:
2.3.2036
Title in English:
COMBINATION OF PEMBROLIZUMAB AND ERIBULIN FOR TREATING TRIPLE-NEGATIVE BREAST CANCERLanguage of the patent:
English
Timeline
Today
3.3.2016EP application
4.5.2022EP Publication
Owner
Name:
Merck Sharp & Dohme Corp.Address:
126 East Lincoln Avenue, Rahway, NJ 07065, US
Name:
Eisai R&D Management Co., Ltd.Address:
6-10, Koishikawa 4-chome Bunkyo-ku, Tokyo 112-8088, JP
Inventor
Name:
MATSUI, JunjiAddress:
Tsukuba-shi Ibaraki 300-2635, JP
Name:
AKTAN, GurselAddress:
North Wales, PA 19454, US
Name:
KARANTZA, VassilikiAddress:
Rahway, NJ 07065, US
Name:
YUAN, RuiRongAddress:
Fort Lee, NJ 07024, US
Name:
FUNAHASHI, YasuhiroAddress:
Tsukuba-shi, Ibaraki 300-2635, JP
Name:
BERRAK, ErhanAddress:
River Vale, NJ 07675, US
Priority
Number:
201562128373 PDate:
4.3.2015Country:
US
Number:
201562264068 PDate:
7.12.2015Country:
US
Classification
Categories:
A61K 39/395, A61K 45/06, A61K 47/26, A61K 31/357, A61P 35/00, A61P 35/04